Lunit Highlights the Effectiveness of AI in Predicting Cancer Treatment Outcomes - Findings to be Presented at ASCO GI 2023
* Lunit to present two abstracts featuring Lunit SCOPE IO, the company's AI biomarker for immune phenotyping * Lunit's presentations this year will highlight the effectiveness of Lunit SCOPE IO as a biomarker to predict treatment outcomes in liver and colon cancer SEOUL, South Korea, Jan. 18,...
Lunit to Supply AI Solution for Chest X-Ray Analysis to Albert Einstein, Latin America's Largest Hospital
* Lunit signed a software license agreement with the Hospital Israelita Albert Einstein,Latin America's top medical institution, to provide its AI-based chest x-ray solution * Under the agreement, Lunit will supply its AI solution for chest x-ray image analysis to the Hospital Israelita Alber...
Lunit AI Can Help Tuberculosis Screening in Prisons, as Published in The Lancet Regional Health - Americas
* Recent study suggests that AI-based x-ray interpretation algorithms may be an efficient means to improve TB case detection among incarcerated populations * Lunit INSIGHT CXR showed the most superior performance among the tested cohort, with greater accuracy and generalizability among subgrou...
Lunit Partners with CARPL.ai to Accelerate AI-Powered Medical Imaging Across Major Overseas Channels
* Lunit signed a global distribution agreement to provide its AI-based radiology solutions for clinical use via CARPL.ai's platform * The partnership will deliver Lunit INSIGHT CXR and Lunit INSIGHT MMG for commercial use in the U.S.,Australia, Brazil, India, and Singapore SEOUL, South Korea,...
Lunit Becomes the First Medical Software Company in Asia-Pacific to Become MDR CE and UKCA Certified
* Lunit becomes first software as a medical device (SaMD) company in APAC to become MDR CE and UKCA certified * MDR and UKCA certifications are required for all Europe and UK commercial medical devices with implementation deadlines set to 2024 SEOUL, South Korea, Nov. 21, 2022 /PRNewswire/ --...
Lunit to Supply AI Platform to Australia's BreastScreen NSW Machine Reading Project
* Lunit's INSIGHT MMG solution has been selected for mammogram screening in Australia's BreastScreen NSW's AI evaluation and clinical integration project * Successful completion of project to be followed by 5-year operation contract with BSNSW to assist radiologists in examining 350,000 women ...
Lunit Highlights the Effectiveness of AI in Acceleration of Immunotherapy Research--Findings to be Presented at SITC 2022
* Lunit to present three abstracts featuring Lunit SCOPE IO, the company's AI biomarker for immune phenotyping. * Lunit's presentations this year will highlight the effectiveness of Lunit SCOPE IO in accelerating immunotherapy clinical trials and drug development. SEOUL, South Korea, Nov. 7, ...
Real-World Application of Lunit INSIGHT to be Spotlighted at RSNA 2022 (Oral Presentations)
* 7 oral presentations and 1 e-poster highlighting Lunit's most up-to-date research on its AI solution for radiology, have been accepted by RSNA * Program will include studies evaluating the performance of Lunit's commercial AI software across massive real-world population groups * Software ...
Lunit Joins World Economic Forum Global Innovators Community
* Lunit invited to join the World Economic Forum's Global Innovators Community, an invitation-only group of the world's most promising start-ups and scale-ups at the forefront of technological and business model innovation * In 2020, Lunit was nominated among hundreds of candidates as one of t...
Lunit Showcases AI Solutions for Radiology at AOCR & KCR 2022
* Lunit participates in the 20th Asian Oceanian Congress of Radiology and 78th Annual Meeting of the Korean Society of Radiology (AOCR & KCR 2022) * Lunit's demonstration focuses on how radiologists and AI solutions can create synergy through combined workflows * Visitors invited to Lunit De...
New Study by Lunit and MGH Validates Effectiveness of AI as Aid in Chest X-Ray Interpretation - Published in JAMA Network Open
* Joint study with Massachusetts General Hospital proves that Lunit's
AI-powered chest x-ray analysis software enhances the overall performance and
efficiency of radiologists SEOUL, South Korea, Sept. 13, 2022 /PRNewswire/ -- A
recent study published in
Lunit Introduces AI for TB Screening to Indonesia Ministry of Health Officials
* Lunit participated in the "Indonesia AI Healthcare Course," organized by South Korean Ministry of Science and ICT as a platform to experience AI image analysis solution and share tuberculosis diagnosis technology * The program aimed to increase awareness of the values of AI-assisted tubercu...
Lunit to Showcase 5 Abstracts at ESMO 2022
* Lunit to present five posters at ESMO 2022 featuring the company's AI-biomarker platform * Studies corroborate the capability of Lunit SCOPE suite to address an expanding set of clinical and research questions based on world-leading digital pathology AI SEOUL, South Korea, Sept. 5, 2022 /PR...
Lunit AI Solution for Breast Cancer Detection Wins Commercial Approval in Taiwan
* Lunit's AI solution for mammography received a class 2 medical device license from the Taiwan Food and Drug Administration * Lunit's latest commercial approval to accelerate expansion in the Taiwanese market SEOUL, South Korea, Aug. 25, 2022 /PRNewswire/ -- Lunit (KRX: 328130.KQ), a leading...
Lunit Announces Financial Results for the First Half of 2022
* Consolidated revenue in the second quarter of 2022 increased by 190% compared to same prior-year period * Total revenue for H1 2022 amounted to KRW 5.48 billion, or 82.5% of the total revenue of last year SEOUL, South Korea, Aug. 12, 2022 /PRNewswire/ -- Lunit (KRX: 328130.KQ), a global pro...
New Immunotherapy Combination Study for Nasopharyngeal Cancer Demonstrates Effectiveness of Lunit AI as Predictive Aid in Treatment Outcome--Published in Clinical Cancer Research
* Recent clinical trial on combination immunotherapy for nasopharyngeal cancer provides evidence for Lunit SCOPE IO's ability to predict patient response. * Analysis indicates Immune-excluded Immune Phenotype acts as a resistance mechanism against combination immunotherapy, further supporting...
AI-based Cancer Solution Pioneer Lunit Makes Market Debut
SEOUL, South Korea, July 21, 2022 /PRNewswire/ -- Lunit, a global provider of AI-powered cancer solutions, announced today that it made its stock market debut on the South Korean KOSDAQ under the ticker "A32813". Lunit's initial public offering of 1,215,800 shares of its common stock was priced a...
